Trial Profile
A Phase 1, Blinded, Randomized, Placebo Controlled, Parallel-Group, Single-Dose, Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 May 2021
Price :
$35
*
At a glance
- Drugs Emodepside (Primary)
- Indications Filariasis; Onchocerciasis
- Focus Adverse reactions; First in man
- 24 Mar 2021 Results of a pooled analysis (NCT03383614and NCT02661178 ) assessing the basic PK including biopharmaceutical features and safety of emodepside in healthy male subjects after single and multiple oral doses as a liquid service formulation published in the British Journal of Clinical Pharmacology
- 24 Aug 2017 Status changed from recruiting to completed.
- 31 Jan 2017 Planned End Date changed from 1 Nov 2016 to 1 Mar 2017.